<i>MEG3</i> and <i>MEG8</i> aberrant methylation in an infant with neuroblastoma

Novak, Estela Maria; Gimenez, Thamiris Magalhaes; Neves, Nathalia Halley; Vince, Carolina C.; Krepischi, Ana Cristina Victorino; Lapa, Rainer Marco López; Cristófani, Lílian Maria; Bendit, Israel; Filho, Vicente Odone

doi:10.1002/pbc.28328

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MEG3 was reported to be significantly downregulated in NB and negatively associated with the international neuroblastoma staging system (INSS) stage (Ye et al, 2020). Moreover, Novak et al (2020) receptors. It has been reported that RAMP1 is expressed in various tissues, including the adrenal gland (Nagae et al, 2000;Cottrell et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…MEG3 was reported to be significantly downregulated in NB and negatively associated with the international neuroblastoma staging system (INSS) stage ( Ye et al, 2020 ). Moreover, Novak et al (2020) reported that MEG3 and EZH2 regulated each other through a negative feedback loop and jointly promoted NB progression, suggesting MEG3 may be a potential treatment target for NB. NPW is a gene encoding neuropeptide protein, which can enhance cortisol secretion from adrenal cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma

Yan

Liu

Cao

et al. 2022

Front. Neuroinform.

View full text Add to dashboard Cite

BackgroundNeuroblastoma is the most common extracranial solid tumor of childhood, arising from the sympathetic nervous system. High-risk neuroblastoma (HRNB) remains a major therapeutic challenge with low survival rates despite the intensification of therapy. This study aimed to develop a malignant-cell marker gene signature (MMGS) that might serve as a prognostic indicator in HRNB patients.MethodsMulti-omics datasets, including mRNA expression (single-cell and bulk), DNA methylation, and clinical information of HRNB patients, were used to identify prognostic malignant cell marker genes. MMGS was established by univariate Cox analysis, LASSO, and stepwise multivariable Cox regression analysis. Kaplan–Meier (KM) curve and time-dependent receiver operating characteristic curve (tROC) were used to evaluate the prognostic value and performance of MMGS, respectively. MMGS further verified its reliability and accuracy in the independent validation set. Finally, the characteristics of functional enrichment, tumor immune features, and inflammatory activity between different MMGS risk groups were also investigated.ResultsWe constructed a prognostic model consisting of six malignant cell maker genes (MAPT, C1QTNF4, MEG3, NPW, RAMP1, and CDT1), which stratified patients into ultra-high-risk (UHR) and common-high-risk (CHR) group. Patients in the UHR group had significantly worse overall survival (OS) than those in the CHR group. MMGS was verified as an independent predictor for the OS of HRNB patients. The area under the curve (AUC) values of MMGS at 1-, 3-, and 5-year were 0.78, 0.693, and 0.618, respectively. Notably, functional enrichment, tumor immune features, and inflammatory activity analyses preliminarily indicated that the poor prognosis in the UHR group might result from the dysregulation of the metabolic process and immunosuppressive microenvironment.ConclusionThis study established a novel six-malignant cell maker gene prognostic model that can be used to predict the prognosis of HRNB patients, which may provide new insight for the treatment and personalized monitoring of HRNB patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…MEG3 was reported to be significantly downregulated in NB and negatively associated with the international neuroblastoma staging system (INSS) stage ( Ye et al, 2020 ). Moreover, Novak et al (2020) reported that MEG3 and EZH2 regulated each other through a negative feedback loop and jointly promoted NB progression, suggesting MEG3 may be a potential treatment target for NB. NPW is a gene encoding neuropeptide protein, which can enhance cortisol secretion from adrenal cells.…”

Section: Discussionmentioning

confidence: 99%